NCT03897309View on ClinicalTrials.gov

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

January 15, 2021

Study Completion Date

April 1, 2021

Conditions
Norovirus Infection
Interventions
BIOLOGICAL

VXA-G1.1-NN

Monovalent GI.1 tableted vaccine

BIOLOGICAL

VXA-G2.4-NS

Monovalent GII.4 tableted vaccine

BIOLOGICAL

Placebo Tablets

Tablets matching in number and appearance to active vaccine doses

Trial Locations (1)

44122

Rapid Medical Research, Cleveland

Sponsors

Lead Sponsor

Vaxart
All Listed Sponsors
lead

Vaxart

INDUSTRY

NCT03897309 - Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines | Biotech Hunter | Biotech Hunter